SCHEMBL3215829

SCHEMBL3215829

CC(C)CC(C)NS(=O)(=O)NC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNPEP Q9H4A4 1/20 0.39
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
LARS1 Q9P2J5 1/20 0.35
ALDH1A1 P00352 3/20 0.35
SLC7A5 Q01650 1/20 0.34
CA14 Q9ULX7 3/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32
CPA1 P15085 1/20 0.32
MMP1 P03956 2/20 0.32
MMP2 P08253 2/20 0.32
MMP9 P14780 2/20 0.32
MMP13 P45452 2/20 0.32
MMP3 P08254 1/20 0.32
MMP7 P09237 1/20 0.32
CA12 O43570 2/20 0.32
CA7 P43166 2/20 0.32
CA9 Q16790 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3204791 0.78 SMN1; SMN2 (0.46) CYP2C19CYP2D6ALDH1A1CA14LMNA
SCHEMBL3202261 0.72 CA14 (0.38) CYP2C19CYP2D6CA14MMP1MMP2
SCHEMBL11394926 0.72 RNPEP (0.36) RNPEPALDH1A1SLC7A5MMP1MMP2
SCHEMBL3217525 0.71 CA12 (0.33) CA14LMNAMMP1MMP2CA12
SCHEMBL23872669 0.69 ALDH1A1 (0.39) RNPEPCYP2C19ALDH1A1CA9CA2
SCHEMBL6728949 0.69 ALDH1A1 (0.46) RNPEPCYP2C19CYP2D6ALDH1A1SLC7A5
SCHEMBL17109066 0.69 ALDH1A1 (0.39) RNPEPCYP2C19ALDH1A1CA9CA2
SCHEMBL12204119 0.69 ALDH1A1 (0.39) RNPEPCYP2C19ALDH1A1CA9CA2
SCHEMBL5126842 0.68 HDAC1 (0.37) MMP2MMP9CA12CA9CA2
SCHEMBL21789772 0.67 GRIA1 (0.39) RNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 RNPEP 335/4885CYP2C19 3912/4885CYP2D6 2131/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 RNPEP 928/4885CYP2C19 4103/4885CYP2D6 1891/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 RNPEP 335/4885CYP2C19 3912/4885CYP2D6 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.